严重烧伤患者连续性肾脏替代治疗中滤器寿命、治疗效果及影响因素
该研究回顾性分析62例严重烧伤患者使用的501个CRRT滤器,比较肝素、甲磺酸萘莫司他、枸橼酸钠三种抗凝方式下滤器寿命,并用logistic回归分析非选择性终止的危险因素。枸橼酸钠组滤器中位寿命31.06 h长于甲磺酸萘莫司他组16.42 h和肝素组14.08 h,且非选择性终止风险低于肝素。作者推荐无禁忌证患者使用枸橼酸钠抗凝。
要点
- 枸橼酸钠组滤器中位寿命31.06 h,长于甲磺酸萘莫司他组16.42 h和肝素组14.08 h。
- 多因素logistic回归显示枸橼酸钠抗凝非选择性终止风险低于肝素抗凝。
- 作者推荐无禁忌证患者使用枸橼酸钠抗凝。
核心结论
- 枸橼酸钠抗凝时滤器寿命明显长于甲磺酸萘莫司他和肝素,同时明显降低非选择性终止风险。
- 作者推荐无禁忌证患者使用枸橼酸钠抗凝。
研究设计与样本
- 回顾性分析62例严重烧伤患者使用的501个CRRT滤器,主要分析全部滤器寿命和治疗效果。
- 采用logistic回归分析非选择性终止滤器的相关危险因素。
主要发现
- 493个滤器中肝素组279例(56.60%),滤器中位寿命14.08 h(第25、75分位数:7.30、21.50)。
- 甲磺酸萘莫司他组128例(26.00%),滤器中位寿命16.42 h(10.49、22.76)。
- 枸橼酸钠组86例(17.40%),滤器中位寿命31.06 h(19.25、48.75)。
- 单个滤器治疗前后电解质指标、肾功能指标和降钙素原水平差异有统计学意义(P < .001)。
- 多因素logistic回归显示枸橼酸钠抗凝非选择性终止风险低于肝素抗凝。
关键数值与推荐
- 肝素组279例(56.60%),滤器中位寿命14.08 h(25th, 75th分位数:7.30, 21.50)。
- 甲磺酸萘莫司他组128例(26.00%),滤器中位寿命16.42 h(10.49, 22.76)。
- 枸橼酸钠组86例(17.40%),滤器中位寿命31.06 h(19.25, 48.75)。
- 单个滤器治疗前后电解质指标、肾功能指标和降钙素原水平差异有统计学意义(P < .001)。
- 作者推荐无禁忌证患者使用枸橼酸钠抗凝。
临床怎么用
- 作者推荐无禁忌证患者使用枸橼酸钠抗凝。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Continuous renal replacement therapy (CRRT) is often disrupted due to various factors, such as patient-related issues, vascular access complications, treatment plans, and medical staff factors. This unexpected interruption is referred to as non-selective filter stoppage and can result in additional treatment expenses. This study conducted a retrospectively analyzed 501 CRRT filters used in 62 patients with severe burns, lifespan and therapeutic effect of all filters were mainly analyzed, used logistic regression analysis was performed to identify risk factors associated with non-selective cessation filters. Out of 493 filters, 279 cases received heparin (56.60%), the median lifespan of the filter was 14.08 h (25th, 75th quantile: 7.30, 21.50); 128 cases were treated with nafamostat mesylate (26.00%), and the median lifespan of the filter was 16.42 h (10.49, 22.76); 86 cases were treated with sodium citrate (17.40%), and the median lifespan of the filter was 31.06 h (19.25, 48.75). In addition, significant differences were observed in the electrolyte index, renal function index, and procalcitonin levels before and after treatment with a single filter (P < .001). Multivariate logistic regression showed that the risk of non-selective cessation of sodium citrate anticoagulants was lower than that of heparin anticoagulation. Overall, CRRT is progressively becoming more prevalent in the treatment of patients with severe burns. The lifespan of individual filters and total patient treatment duration showed a consistent upward trend. The filter's lifespan was notably greater during sodium citrate anticoagulation when compared to nafamostat mesylate and heparin, meanwhile notably reducing the risk of non-selective cessation. Therefore, we recommend sodium citrate for anticoagulation in patients without any contraindications.
引用
- Yue Q, Wu H, Xi M, et al. Filter Lifespan, Treatment Effect, and Influencing Factors of Continuous Renal Replacement Therapy for Severe Burn Patients. J Burn Care Res. 2024. PMID: 38113522. doi:10.1093/jbcr/irad196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。